A Phase I Study of KO-947 in Inoperable or Metastatic Recurrent or Persistent Solid Tumors

Full Title

KO-ERK-001: A Phase 1 First-in-Human Study of KO-947 in Locally Advanced Unresectable or Metastatic, Relapsed and/or Refractory Non-Hematological Malignancies

Purpose

The purpose of this study is to find the highest dose of the investigational drug KO-947 that can be given safely in patients with inoperable or metastatic solid tumors that have come back or continued to grow despite prior therapy. KO-947 works by inhibiting ERK, a protein involved in the growth and spread of some cancers. It is given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have an inoperable or metastatic solid tumor that has come back or continued to grow despite prior therapy. Examples include select non-small cell lung cancers and head and neck cancers.
  • At least 2 weeks must pass between the completion of previous treatment and entry into the study.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. David Hyman at 646-888-4544.

Protocol

17-150

Phase

I

Investigator

Co-Investigators